Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection

This study tests whether it is safe and feasible to give patients with hepatocellular carcinoma (liver cancer) an infusion of their own (autologous) immune cells, called cytokine-induced killer (CIK) cells, after they have had surgery to remove their liver tumor. The patient's own blood cells are collected and grown in a laboratory to create the CIK cells, which are then given back to the patient through six intravenous infusions over about two months. Patients are followed for six months to check for side effects and early signs of whether the cancer returns.

NCT Number	NCT07709299
Lead Sponsor	Royan Institute Collaborators: Bahar Tashkhis Teb, Kian Immune Cell Company
Conditions	Hepatocellular Carcinoma (HCC)
Enrollment	6 participants
Start Date	2026-07
Primary Completion	2028-07 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2026-07-16